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Abstracts / Urological Science 26 (2015) S50eS81 S51Discussion: Adenomatoid tumors are the most common paratesticular
neoplasms and involve approximately 30% of all paratesticular masses.
There are several theories about their histogenesis: mesothelial, Müllerian,
mesonephric, and endothelial origin. The mesothelial origin is the most
widely accepted. Adenomatoid tumours usually involve the genitourinary
system in both males and females. Fallopian tubes, ovaries and uterus are
common areas for females, and epididymis, testes, spermatic cord, ejac-
ulatory ducts are common in males. These tumors are usually located in
the tail part of the epididymis usually as a separate mass with a mean age
of presentation between 30 to 40 years. Clinical presentation can vary from
asymptomatic small masses to very painful masses in the scrotum region
which can be confused for torsion. Ultrasonography is the initial investi-
gation of choice with high sensitivity and speciﬁcity rates. Ultrasound
examination demonstrates well circumscribed uniformly hypoechoic
mass, that are usually avascular but may demonstrate internal vascularity
on colour ﬂow Doppler imaging. MRI helps in diagnosis as the lesion ap-
pears hypointense to surrounding parenchyma arising from testicular
surface and enhances less than the normal testis on post contrast
administration. By considering rare benign intratesticular tumors in the
differential diagnosis of testicular masses, normal levels of preoperative
serum tumor markers combined with intraoperative histologic examina-
tion can offer the surgeon to clues of this rare benign tumor. The intra-
operative frozen section should be considered.
NDP005:
TESTICULAR CAPILLARY HEMANGIOMA: CASE REPORT
Yi-Chu Lin, Sheng-Han Tsai, Shin-Shu Chang. Department of Urology, Cheng
Hsin General Hospital, Taipei, Taiwan
Case Presentation: A 17 year-old boy found left testicular mass with
tenderness by himself, and then visited our urology outpatient department
for help. At OPD, physical examination showed a hard nodule in left testis
with tenderness, B-HCG and AFP were normal. Then sonography of
scrotum and CT of abdomen was arrange for further evaluation. Both of
image examinations showed a small hypervascular nodule in lower pole of
left testicle, but no deﬁnite lymphadenopathy or mass in the retroperito-
neal space or inguinal regions were found. For hypervascular tumor of
testis, differential diagnosis included vascular malformation, or germ cell
tumor. As germ cell tumor cannot be rule out, surgical intervention was
suggested. The patient was admitted and operation was arranged on.
During operation, a well circumscribed tumor in left scrotum near
epididymal tail was found, the tumorwas homogenous, brownish and easy
bleeding, tumor size was about 1.5 x1.5 cm, frozen section of tumor was
sent and showed hemangioma with low N/C ratio microscopically.
Therefore, tumor excision with testicle sparing was done according to
frozen section result. The ﬁnal pathology report of the tumor was capillary
hemangioma, which was a benign testicular tumor.
Discussion: Testicular capillary haemangioma is an exceptionally rare
tumor. Capillary haemangioma of the testis can be similar to malignant
testicular tumors on clinical presentation, as well as on ultrasonography
and computed tomography, and therefore should be included in the
intraoperative differential diagnosis. Because of the benign nature of this
lesion, conservative surgical treatment by means of tumor enucleation
with preservation of the testis is possible, if intraoperative examination of
frozen sections of representative tissue can be performed.NDP006:
GNRH AGONIST INDUCED ACUTE FULMINANT HEPATITIS IN PATIENT
WITH PROSTATE CANCER-CASE REPORT
Yu-Cing Juho, Sheng-Tang Wu, Tai-Lung Cha, Guang-Haun Sun, Sun-Yran
Chang, Dah-Shyong Yu. Division of Urology, Departments of Surgery, Tri-
Service General Hospital, National Defense Medical Center, Taipei, Taiwan
An 85 year old man with history of locally advanced prostate cancer
received monotherapy with anti-androgen since 1997. Due to prostate
speciﬁc antigen progression (>500 ng/mL), systemic chemotherapy with
taxotere was performed one year ago. Because of intolerance for chemo-
therapy, the patient went to our outpatient department for secondaryopinion.We then applied complete androgen blockadewith anti-androgen
and GnRH agonist. Three days later, the patient was sent to emergent
department due to poor appetite and conscious disturbance for two days.
History taking revealed no hepatitis B, hepatitis C, drug abuse and alcohol
consumption. Physical examination showed normal vital sign without
scleral icterus. There was no tea color urine or clay stool found. The blood
biochemistry revealed abnormal data with AST 1637 U/L, ALT 3413 U/L and
total bilirubin 0.6 mg/dL. Abdominal sonography at emergent department
found fatty liver without distention of gallbladder. Under the impression of
acute fulminant hepatitis, the patient was admitted for conservative
treatment.
A series of examination was arranged after admission. HAV IgM and HCV
antibody showed negative. Negative of HBV surface antigen with positive
of HBV surface antibody were noted. Other serologic examination revealed
negative ﬁnding of virus infection including CMV, EBV and HSV. Autoim-
mune hepatitis was also excluded by normal range of ANA titer. Other
cause including ischemia, acetaminophen, toxin and alcohol were unlikely
due to lack of evidence.
Under supportive treatment with adequate hydration and silymarin
therapy, the conscious got improved and liver enzyme decreased gradu-
ally. The ﬁnal data of AST/ALT was 597/337 (U/L) one week later after
admission. According the history and serologic examination, this episode
of acute fulminant hepatitis might be induced by GnRH agonist.
Conclusion: GnRH agonist is used as hormone therapy for controlling
prostate cancer with anti-androgen. However, drug toxicity induced acute
fulminant hepatitis was observed in this case. We should pay more
attention for symptom and liver function in patients who received GnRH
agonist therapy.
NDP007:
PARATESTICULAR DEDIFFERENTIATED LIPOSARCOMAdA CASE REPORT
You-Chiuan Chien, Chun-Chi Chen, Bai-fu Wang, Kuo-Chin Wei. Divisions
of Urology, Department of Surgery, Changhua Christian Hospital, Changhua,
Taiwan
Background: Paratesticular liposarcomas are rare tumors which account
for 12% of all liposarcomas. They must be differentiated from tumors of
testicular origin which have extension to the spermatic cord.
Clinical Case: We reported a case of a 72-year-old male who had pre-
sented with a painless swelling mass in the left hemiscrotum, which
was of 10 years' duration. Initially, a clinical impression of scrotal tumor
was made; however, CT of the scrotum revealed a spermatic cord mass.
The mass was managed by excisional biopsy and later pathology re-
ported dedifferentiated liposarcoma with margin involvement. Meta-
static work-up, which included CT of the abdomen and pelvis and chest
X ray, did not reveal any distant metastasis. Patient underwent high
orchidectomy with skin excision. Histopathological studies conﬁrmed
the diagnosis of dedifferentiated liposarcoma with clear surgical
margin.
Conclusion: Liposarcomas of the spermatic cord represent a rare type of
tumors, which are often misdiagnosed preoperatively. Being a rare disease
and varied type of presentation, paratesticular liposarcoma should be
considered as a possibility during the differential diagnosis of fat con-
taining inguino-scrotal mass.NDP008:
TUMOR MARKER OREINTATED CHEMOTHERAPY IN CANCER OF
UNKNOWN PRIMARY SITE: A CASE REPORT AND LITERATURE REVIEW
Yu-De Wang, Chao-Hsiang Chang, Chi-Rei Yang. Department of Urology,
China Medical University Hospital, Taichung, Taiwan
A case of a 56-year-old woman, who presented with acute abdomen, was
diagnosed retroperitoneal poorly differentiated carcinoma of unknown
primary site without ovarian involvement. We encountered failure
attempt of tumor excision initially. In spite of a primary lesion was not
conﬁrmed, we performed tumor maker (CA-199) orientated chemo-
therapy with the regimen of carboplatin and paclitaxel according to tumor
markers and pathological ﬁndings.
